GSK-2636771
N/A
Report date: 2026/05/20 20:02:01
NME
Base Information
Drug NameGSK-2636771
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[29]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[5]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A
Develop Information
Active CompaniesGlaxosmithkline PlcNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesYonsei University
Active Indications +[28]
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A